Back

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: SGLT2 inhibitors in heart failure: prevention and treatment Comorbidities ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Petar Kalaydzhiev

University Hospital Tsaritsa Yoanna, Sofia (Bulgaria)

3 More presentations in this session

Presentation thumbnail
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation
Associate Professor V. Vintila (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.
Doctor L. Spadafora (Latina, IT)
Abstract Slides Video
Presentation thumbnail
THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.
Doctor S. Das (Boston, US)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of sglt2-inhibitors on polygraphic parameters in elderly patients affected by heart failure and sleep apnea
thumbnail
Congress Presentation
The effect of GLP-1 receptor agonists on obstructive sleep apnea in ambulatory patients with HFpEF, obesity, and type 2 diabetes.
thumbnail
Congress Presentation
Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources